COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis.

Publication date: Jan 10, 2025

This systematic review evaluated the effectiveness and side effects of various COVID-19 vaccines, with a focus on Trinidad and Tobago. The Pfizer-BioNTech and Moderna vaccines demonstrated the highest efficacy, particularly against COVID-19 variants, while Janssen and Sinopharm were comparatively less effective. mRNA vaccines, such as Pfizer-BioNTech and Oxford-AstraZeneca, were associated with more frequent and severe side effects, including soreness, fever, and cardiovascular issues. The review also identified significant gaps in the current scientific literature regarding COVID-19 vaccination issues in Trinidad and Tobago. These gaps highlight the need for comprehensive research to address vaccination challenges, including public health communication, equitable access, and local perceptions of vaccine safety. This analysis provides a foundation for developing targeted strategies to improve vaccine effectiveness in the region.

Open Access PDF

Concepts	Keywords
Astrazeneca	AstraZeneca
Oxford	COVID-19
Scientific	Janssen
Soreness	modern
Vaccines	Novavax
	Pfizer-BioNTech
	Sinopharm
	Trinidad and Tobago
	vaccine effectiveness (VE)

Semantics

Type	Source	Name
disease	MESH	COVID-19
drug	DRUGBANK	Dimethyl sulfone
drug	DRUGBANK	Etodolac
drug	DRUGBANK	Albendazole
disease	MESH	emergency
disease	MESH	infections
disease	IDO	country
disease	IDO	intervention
disease	IDO	infection
disease	MESH	death
disease	IDO	nucleic acid
disease	MESH	joint pain
disease	MESH	lymphadenopathy
disease	MESH	dyspnea
disease	MESH	syndrome
disease	MESH	transverse myelitis
disease	MESH	palsy
disease	MESH	small fiber neuropathy
disease	MESH	sclerosis
disease	MESH	autoimmune encephalitis
disease	MESH	ischemic strokes
disease	MESH	Myocarditis
disease	MESH	Pericarditis
disease	MESH	chest pain
disease	IDO	site
disease	MESH	Thrombocytopenia
disease	IDO	facility
disease	IDO	ribonucleic acid
disease	IDO	pathogen
pathway	REACTOME	Adaptive Immune System
disease	MESH	Long COVID
pathway	REACTOME	Immune System
disease	IDO	process
disease	MESH	allergic reactions
drug	DRUGBANK	Etoperidone
disease	MESH	marital status
disease	IDO	quality
drug	DRUGBANK	Esomeprazole
disease	MESH	lifestyles
disease	MESH	cancer
disease	MESH	hypertension
drug	DRUGBANK	Gold
disease	MESH	anaphylaxis
drug	DRUGBANK	Cysteamine
disease	MESH	thrombosis
drug	DRUGBANK	L-Isoleucine
drug	DRUGBANK	Tacrine
disease	MESH	sid
drug	DRUGBANK	Coenzyme M
drug	DRUGBANK	Tropicamide
drug	DRUGBANK	Imipramine
disease	IDO	blood
disease	MESH	Breakthrough Infection
disease	MESH	Guillain Barre Syndrome
disease	MESH	Venous Thrombosis
disease	MESH	Inflammation
disease	MESH	Postvaccinal Encephalitis
drug	DRUGBANK	Sulfasalazine
disease	MESH	Immune Thrombocytopenia
disease	IDO	protein
drug	DRUGBANK	Hyaluronic acid
drug	DRUGBANK	Bismuth subgallate
disease	MESH	Contraindications

Original Article

(Visited 1 times, 1 visits today)